Does combined pelvic and para-aortic lymphadenectomy improve survival for Endometrial Cancer?
The question of whether combined pelvic and para-aortic lymphadenectomy (PPaLND) improves survival in endometrial cancer has been studied for years, but the answer depends on the patient's risk level. For intermediate- and high-risk endometrial cancer, some evidence suggests a survival benefit from adding para-aortic lymph node removal to pelvic lymph node removal. However, for low-risk or early-stage type I cancers, studies have not shown a clear survival advantage. The decision is complex and should be made with your oncology team based on your specific cancer characteristics.
What the research says
A 2020 meta-analysis of 13 studies including 7,349 patients found that combined pelvic and para-aortic lymphadenectomy (PPaLND) was associated with improved overall survival and disease-free survival compared to pelvic lymphadenectomy alone in intermediate- and high-risk endometrial cancer 8. This suggests that for women with higher risk of lymph node spread, removing both pelvic and para-aortic nodes may offer a survival benefit.
However, other studies have not found a survival benefit. A 2020 retrospective study of 333 women with type I endometrial cancer reported no difference in overall survival between those who had no lymphadenectomy, pelvic only, or combined pelvic and para-aortic lymphadenectomy 7. Similarly, a 2022 study of 281 patients with early-stage grade 3 endometrioid and non-endometrioid cancers found no significant difference in recurrence-free or overall survival between pelvic alone and combined lymphadenectomy 9.
A more recent systematic review and meta-analysis (2026) of 14 studies (25,432 patients) noted that the effect of PPaLND on overall survival was inconsistent in unadjusted models, but adjusted analyses suggested a potential benefit in certain subgroups 2. The authors emphasized that the evidence is largely from observational studies, and the survival benefit may be limited to patients with higher recurrence risk.
Importantly, lymphadenectomy carries risks such as longer surgery time, more blood loss, and potential complications like lymphedema 7. The decision to perform PPaLND should balance potential survival benefits against these risks, especially for lower-risk patients where the benefit is less clear.
What to ask your doctor
- Based on my cancer stage, grade, and molecular subtype, what is my risk of lymph node spread?
- Would you recommend pelvic lymphadenectomy alone or combined pelvic and para-aortic lymphadenectomy for my case?
- What are the potential benefits and risks of adding para-aortic lymph node removal to my surgery?
- How does my age, overall health, and tumor characteristics (like LVSI or histology) affect this decision?
- Are there any ongoing clinical trials or newer evidence that might influence the recommendation?
This question is drawn from common patient questions about Oncology and answered using cited medical research. We do not provide individualized advice.